Literature DB >> 2415134

Inhibition of HTLV-III/LAV replication by foscarnet.

P S Sarin, Y Taguchi, D Sun, A Thornton, R C Gallo, B Oberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2415134     DOI： 10.1016/0006-2952(85)90392-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  27 in total

1.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

Authors:  L Vrang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Treatment of the acquired immune deficiency syndrome.

Authors:  S Gupta; M S Gottlieb
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

5.  Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.

Authors:  M C Starnes; Y C Cheng
Journal:  Virus Genes       Date:  1989-05       Impact factor: 2.332

6.  Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.

Authors:  K B Frank; P A McKernan; R A Smith; D F Smee
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 7.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry.

Authors:  K Mori; D J Ringler; R C Desrosiers
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

Authors:  E Matthes; P Langen; M von Janta-Lipinski; H Will; H C Schröder; H Merz; B E Weiler; W E Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

10.  Penetration of foscarnet into cerebrospinal fluid of AIDS patients.

Authors:  F Raffi; A M Taburet; B Ghaleh; A Huart; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.